Gharieb, Shimaa Abdallah; Dorgham, Yousra; Abdelgawad, Mohamed; Abdelhai, Shaimaa Farouk published the artcile< Survival of glioblastoma multiforme patients treated with hypofractionated radiotherapy with integrated boost plus temozolomide>, SDS of cas: 112-63-0, the main research area is anticancer temozolomide radiotherapy prognosis glioblastoma.
Despite recent advances in multimodal treatments, the glioblastoma multiforme (GBM) prognosis remains poor. Hypofractionated radiotherapy regimens have been increasingly adopted for treatment of glioblastoma. To assess the survival rate when using hypofractionated radiotherapy with simultaneous integrated boost concurrently with temozolomide in treatment of GBM. The prospective study was conducted to forty-eight GBM patients referred to the Clin. Oncol. & Nuclear Medicine Department, Zagazig University Hospitals, from August 2019 to August 2021. The patients weres divided in two arms, Arm A include 24 patients treated prospectively by Hypofractionated radiotherapy with simultaneous integrated boost at a dose 50 Gy in 16 fractions, 3.12 Gy per fraction to high-risk planning target volume (PTV) and 40 Gy in 16 fractions, 2.5 Gy per fraction to low-risk PTV concurrently with TMZ and compared with Arm B that include 24 patients treated prospectively by conventional radiotherapy at a dose 60Gy / 30 fractions (phase I 46 Gy / 23 fractions and phase II 14 Gy / 7 fractions) concurrently with TMZ. Main outcome measures: Hypofractionated radiotherapy with integrated boost outcomes. For group A, 6 mo OS (78.4%) and 12 mo OS (43.6%), group B, 6 mo OS (75%) and 12 mo OS (52.5%). For group A the 6 mo PFS rate was (59.2%) while 12 mo PFS rate was (43.1%).For group B the 6 mo PFS rate was (50.5%) while 12 mo PFS rate was (39.8%) with no statistically significant difference between both groups. Hypofractionated radiotherapy shows promising comparable survival outcomes to conventional radiotherapy.
Latin American Journal of Pharmacy published new progress about Antitumor agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, SDS of cas: 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics